PowerBacGWAS: a computational pipeline to perform power calculations for bacterial genome-wide association studies

Francesc Coll1✉, Theodore Gouliouris2,3, Sebastian Bruchmann4, Jody Phelan1, Kathy E. Raven2, Taane G. Clark1,5, Julian Parkhill4 & Sharon J. Peacock2

Genome-wide association studies (GWAS) are increasingly being applied to investigate the genetic basis of bacterial traits. However, approaches to perform power calculations for bacterial GWAS are limited. Here we implemented two alternative approaches to conduct power calculations using existing collections of bacterial genomes. First, a sub-sampling approach was undertaken to reduce the allele frequency and effect size of a known and detectable genotype-phenotype relationship by modifying phenotype labels. Second, a phenotype-simulation approach was conducted to simulate phenotypes from existing genetic variants. We implemented both approaches into a computational pipeline (PowerBacGWAS) that supports power calculations for burden testing, pan-genome and variant GWAS; and applied it to collections of Enterococcus faecium, Klebsiella pneumoniae and Mycobacterium tuberculosis. We used this pipeline to determine sample sizes required to detect causal variants of different minor allele frequencies (MAF), effect sizes and phenotype heritability, and studied the effect of homoplasy and population diversity on the power to detect causal variants. Our pipeline and user documentation are made available and can be applied to other bacterial populations. PowerBacGWAS can be used to determine sample sizes required to find statistically significant associations, or the associations detectable with a given sample size. We recommend to perform power calculations using existing genomes of the bacterial species and population of study.
Bacterial genome-wide association studies (GWAS) are a group of comparative genomics techniques aimed at identifying genetic variants in bacterial genomes that correlate with a phenotypic trait that is variable in a population. The introduction of bacterial GWAS became possible as a result of the increase in the number of whole-genome sequenced isolates. In the last few years, bacterial GWAS have been applied to study the genetic basis of a range of bacterial traits including antibiotic susceptibility, susceptibility to disinfectants, host specificity, transmissibility, carriage duration, adaptation to humans, disease presentation or clinical infectious disease phenotypes, invasiveness, and disease severity and outcomes. Such studies have been influenced by multiple factors which vary strongly between bacterial species such as population structure, gene presence/absence, homoplasy and phenotype heritability. It is therefore not possible to create common statistical methods of estimating power in GWAS studies such as those used in well-studied human populations. To estimate the sample sizes required to detect phenotype-genotype associations in bacteria we implemented two new approaches based directly on real bacterial genomes and phylogenies (Fig. 1). In the first approach (sub-sampling approach), we take a known genotype-phenotype relationship and sequentially sub-sample the population to reduce sample sizes, allele frequency (AF) and effect sizes, to discover at which sub-sample sizes we can still recover the known associations. In the second (phenotype-simulation approach), phenotypes are simulated from randomly selected genetic variants meeting a range of parameters: minor allele frequency (MAF), effect size and sample size. We then perform GWAS to identify the sample size needed to recover the simulated genotype-phenotype relationship. Both approaches require the use of an existing collection of whole-genome sequenced strains of the same species (Fig. 1). The sub-sampling approach additionally requires a measured phenotype and list of known causal variants. In any case, bacterial genomes are not simulated or modified; only phenotype strains’ labels are changed or simulated to achieve the desired combination of parameters.

Selection of strain collections and known genotype-phenotype relationships. Table 1 shows the strain collections used in this study. These collections were assembled from published datasets of whole-genome sequenced strains to include a representative of a gram-positive organism (E. faecium), a gram-negative (K. pneumoniae) and a species of limited genetic diversity (M. tuberculosis). To test the effect of strain diversity in a population on the power of detecting causal variants, we assembled a population representative of the species’ overall strain diversity (hereafter referred to as species-wide population), and a second population of lower genetic diversity, made up of samples from a single clade (single-clade population). Table 1 summarises the overall genetic diversity of each population in terms of pan-genome size, number of SNP sites and average pairwise genetic distance.

Next, we searched for a known antimicrobial resistance (AMR) phenotype-genotype relationship in each population that could be used to perform power calculations (see Methods section for rationale and selection criteria of AMR phenotypes). For the species-wide E. faecium collection (n = 1432), we could use kanamycin resistance (35.3% resistant, 23.3% susceptible, 41.4% not tested) caused by the aminoglycoside resistance aph(3’)-IIIa gene46 (AF = 56.3%, odds ratio (OR) = 1083) and streptomycin resistance for the single-clade A1 population (n = 761, 34.5% resistant, 60.3% susceptible and 5.2% not tested) determined by the streptomycin-resistance ant(6’)-Ia gene43 (AF = 34%, OR = 8986) (Table 1). For K. pneumoniae, we used meropenem resistance (21% resistant, 69.1% susceptible, 9.9% not tested) caused mainly by bbraT,C carbapenemase (AF = 12%, OR = 180) for the species-wide population (n = 2628), but could not use it for the single-clade ST288 population (n = 1193) due to the unbalanced proportion of resistant (95.4%) and susceptible cases (1.3%). Isoniazid resistance was used for both M. tuberculosis populations (n = 2655, AF = 20%, OR = 220; n = 1139, AF = 13%, OR = 166), which is determined by well-known katG mutations32,33.

Application and interpretation of power calculations: sub-sampling approach. Figure 2 and Supplementary Table 1 show the sample sizes required to detect known AMR genotype-phenotype relationships with 80% power as obtained by the sub-sampling approach. These results show that, as expected, the larger the effect size and AF of causal variants, the smaller the sample sizes required to detect them using a GWAS. The pan-genome GWAS, conducted for E. faecium and K. pneumoniae populations to detect acquired AMR genes, yielded very comparable results, both between populations of the same species and across species. Specifically, a sample size of 500 to 700 genomes was enough to detect moderate (OR = 5) to very large (OR = 100) effect sizes of genes present in at least 10% of bacterial populations.
the population (Supplementary Table 1); or 400–600 for causal genes of very large effect sizes (OR = 100) at 5% frequency, depending on the bacterial population studied. Larger sample sizes of at least 800–1100 genomes were needed to detect genes of moderate effect sizes at 5% frequency. Genes of small effect sizes (OR = 1.5) could not be detected using the maximum sample sizes available in our collections. Power calculations for M. tuberculosis showed that the bacterial population had an effect on the power to detect causal mutated genes in a burden GWAS: lower sample sizes were required for the population with lower diversity (single-clade) compared to the species-wide population, to detect genes of the same MAF and effect sizes (Supplementary Table 1).

Application and interpretation of power calculations: phenotype simulation approach. The phenotype simulation approach allowed us to test the effect of a wider range of parameters on the power to detect acquired genes (pan-genome GWAS), individual

Fig. 1 Approach to bacterial GWAS power calculations. Four steps were implemented to conduct power calculations. First, known or randomly sampled causal variants are chosen from existing genotypes, in the sub-sampling or phenotype simulation approach, respectively. In the latter, causal variants meeting a range of selected MAF and degree of homoplasy are selected. Second, phenotypes are either modified from existing ones (sub-sampling approach) or simulated from randomly selected genotypes (phenotype simulation approach) to achieve the range of chosen sample sizes and effect sizes (or heritability values). Third, a genome-wide association study (GWAS) is conducted for each combination of parameters and p-values of causal variant extracted. And forth, power is calculated as the proportion of GWAS replicates in which the causal variant is above the Bonferroni-corrected genome-wide significance threshold.
Table 1: Bacterial species, strain collections and antibiotic susceptibility phenotypes used in this study.

| Bacterial species       | Strain collection | # of isolates (diversity) | LD: median R² (IQ range) | # of SNP sites | # of genes in pan-genome | AMR phenotype (% R and S)a | AMR causal variants | AMR causal variants: AFb, OR and GWAS p-value |
|-------------------------|-------------------|---------------------------|--------------------------|----------------|---------------------------|-----------------------------|---------------------|---------------------------------------------|
| **Enterococcus faecium**| Species-wide      | n = 1432 (5.6 SNPs/kb)    | 0.65 (0.37–0.95)         | 263,875        | 11,800                    | Kanamycin susceptibility (35.3%, 23.3%) | aph(3')-IIIa       | AF: 56.3% OR: 1083 p-value: 8.25 × 10⁻¹⁴⁵ |
|                         | Single-clade      | n = 761 (2.4 SNPs/kb)     | 0.50 (0.28–0.98)         | 50,790         | 5443                      | Streptomycin susceptibility (34.5%, 60.3%) | ant(6)-Ia/aad(6)   | AF: 34% OR: 8986 p-value: 1.61 × 10⁻⁵¹ |
| **Klebsiella pneumoniae**| Species-wide      | n = 2628 (5.2 SNPs/kb)    | 0.67 (0.37–1.00)         | 543,165        | 30,772                    | Meropenem susceptibility (21%, 69.1%) | blaoPC             | AF: 12% OR: 180 p-value: 8.90 × 10⁻¹¹⁰ |
|                         | Single-clade      | n = 1193 (0.11 SNPs/kb)   | 0.78 (0.50–0.96)         | 46,541         | 23,708                    | Meropenem susceptibility (95.4%, 1.3%) | blaoPC             | AF: 72% OR: NAc p-value: NAc             |
| **Mycobacterium tuberculosis**| Species-wide      | n = 2655 (0.2 SNPs/kb)    | 0.86 (0.39–1.00)         | 93,995         | 21,678                    | Isoniazid susceptibility (30.9%, 66.4%) | nsSNPs in katG   | AF: 20% OR: 220 p-value: 2.54 × 10⁻¹⁰¹ |
|                         | Single-clade²     | n = 1139 (0.05 SNPs/kb)   | 0.98 (0.40–1.00)         | 24,467         | 10,130                    | Isoniazid susceptibility (23.8%, 71.7%) | nsSNPs in katG   | AF: 13% OR: 166 p-value: 6.40 × 10⁻⁷³   |

Summary table of strain collections used in this study. The average diversity (third column) was calculated as the mean pairwise genetic distance between isolates, expressed as number of SNPs per kilobase. The number of SNP sites in the chromosome (forth column; extracted from the VCF file) and number of genes in the pan-genome (fifth column; extracted from Panaroo’s output), both calculated across all isolates, indicate the degree of diversity within each collection. The last columns show the AMR phenotypes and causal variants used by the sub-sampling approach to perform power calculations. The single-clade collections correspond to clade A1 isolates for *E. faecium*, CC258 isolates for *K. pneumoniae*, and lineage 4.3 isolates for *Mycobacterium tuberculosis*.

a The percentage of resistant and susceptible isolates may not amount to 100%, as a subset of isolates were not tested.
b The MAF was calculated in the whole population not in just the samples phenotyped for the antibiotic in question.
c The unbalanced number of cases and controls prevented running GWAS.

SNPs/kb: Single Nucleotide Polymorphisms per kilobase, AF: allele frequency, OR: odds ratio, nsSNP: non-synonymous SNPs, LD: linkage disequilibrium.
SNPs (variant GWAS) and mutated genes (burden testing GWAS) causing binary phenotypes. Table 2 and Supplementary Fig. 1 show the sample sizes required to detect causal acquired genes with 80% power in a pan-genome GWAS. These sample sizes are comparable to those obtained by the sub-sampling approach for the detection of acquired AMR genes (Supplementary Table 1). Specifically, a minimum of 500–600 genomes were needed to detect moderate (OR = 5) to very large (OR = 100) effect sizes of genes of 10% frequency, regardless of the bacterial population considered (Table 2); and 200–500 or less to detect genes of 25% frequency. Larger sample sizes of at least 2000–2500 genomes are needed to detect genes of 2.5% frequency. In addition, we tested the effect of increasing heritability and found that, as expected, the higher the heritability of causal
Higher heritability resulted in more power to detect common population, although they were lower when using burden testing. The proportion of GWAS replicates in which the causal AMR gene is above the Bonferroni-corrected genome-wide significance threshold. The black and dotted horizontal line marks 80% power. Sample sizes are represented in the x-axis. The colour of lines denotes different AF whereas point shapes and line types effect sizes in odds ratio units. The power calculation results presented here are those for the species-wide populations, see Supplementary Table 1 for sample sizes required in both species-wide and single-clade populations. Pan-genome GWAS was run to detect acquired AMR genes in E. faecium (a) and K. pneumoniae (b) populations. A burden test GWAS was applied to M. tuberculosis (c).

Table 2 Sample sizes required to detect causal genes of different MAF and effect sizes in a pan-genome GWAS.

| Bacterial species | Strain collection | Gene frequency (%) | Effect size (odds ratio) |
|-------------------|-------------------|--------------------|-------------------------|
|                   |                   |                    | Small (1.5) | Moderate (5) | Large (10) | Very large (100) |
| Enterococcus faecium (pan-genome GWAS) | Species-wide (n = 1432) | 1 | - | - | - | - |
|                   |                   | 2.5 | - | - | - | 1100 |
|                   |                   | 5 | - | 1000 | 600 | 500 |
|                   |                   | 10 | - | 500 | 400 | 200 |
|                   |                   | 25 | - | 200 | 200 | 100 |
|                   | Single-clade (n = 1531) | 0-1 | - | - | - | - |
|                   |                   | 2.5 | - | - | - | 1400 |
|                   |                   | 5 | - | - | - | - |
|                   |                   | 10 | - | 600 | 400 | 300 |
|                   |                   | 25 | - | 300 | 200 | 100 |
| Klebsiella pneumoniae (pan-genome GWAS) | Species-wide (n = 2628) | 1 | - | - | - | - |
|                   |                   | 2.5 | - | 2500 | 1600 | 1200 |
|                   |                   | 5 | - | 1500 | 1000 | 700 |
|                   |                   | 10 | - | 600 | 400 | 300 |
|                   |                   | 25 | - | 500 | 400 | 200 |
|                   | Single-clade (n = 1193) | 0-1 | - | - | - | - |
|                   |                   | 2.5 | - | - | - | 1000 |
|                   |                   | 5 | - | 900 | 700 | 500 |
|                   |                   | 10 | - | 500 | 300 | 200 |
|                   |                   | 25 | - | 300 | 200 | 100 |
| Mycobacterium tuberculosis (pan-genome GWAS) | Species-wide (n = 2655) | 1 | - | - | - | - |
|                   |                   | 2.5 | - | 2000 | 1300 | 1000 |
|                   |                   | 5 | - | 1100 | 700 | 500 |
|                   |                   | 10 | - | 900 | 500 |
|                   |                   | 25 | - | 300 | 200 | 100 |
|                   | Single-clade (n = 1139) | 0-1 | - | - | - | - |
|                   |                   | 2.5 | - | - | - | 1000 |
|                   |                   | 5 | - | 900 | 700 | 500 |
|                   |                   | 10 | - | 500 | 300 | 200 |
|                   |                   | 25 | - | 300 | 200 | 100 |

MAF minor allele frequency, - non-detectable with 80% power.

Results of running GWAS power calculations applying the phenotype simulation approach (binary phenotype, full heritability assumed). This table shows the minimum sample sizes required to detect acquired genes of different effect sizes (in odds ratio units) and gene frequencies in a pan-genome GWAS with 80% power, in both species-wide and single-clade populations.

genes, the lower the sample sizes required to detect them (Supplementary Table 2). Increasing heritability resulted in a sharp decrease in sample sizes required to detect common genes (i.e. 25% frequency), but had no, or little effect, on the detection of rarer genes (e.g. 2.5% frequency).

We next conducted power calculations for the detection of individual SNPs (SNP GWAS Supplementary Fig. 2) and mutated genes (burden GWAS, Supplementary Fig. 3). We found that burden testing had more power (i.e. required lower sample sizes to detect the same effect sizes) than a SNP GWAS and could detect mutated genes down to 2.5% MAF, not detectable by a SNP GWAS (Table 3). Here, the MAF of genes in a burden test refers to the percentage of samples carrying one or multiple SNPs in the same gene. The sample sizes required to detect SNPs of the same MAF and effect size (Table 3) with 80% power varied by population, although they were lower when using burden testing. Higher heritability resulted in more power to detect common SNPs (Supplementary Table 3) but had little effect on the detection of rarer SNPs. Next, we studied the effect that the degree of homoplasy may have on the power to detect causal variants.

**Effect of homoplasy level.** The degree of homoplasy of causal SNPs, that is, the number of times SNPs arose independently in the phylogeny, had a big impact on the ability of GWAS to detect them (Fig. 3). GWAS were more powered at detecting highly homoplasic SNPs, although the effect was less pronounced for low-MAF SNPs (Supplementary Table 4). As an example, highly homoplasic SNPs (acquired 50 to 100 times) in E. faecium at 10% MAF could be detected with half the sample sizes needed to detect low homoplasic SNPs (acquired 1–5 times) of the same MAF, regardless of their effect size, a pattern we observed in all bacterial populations studied. We next studied the effect of the bacterial population on the power to detect SNPs. In
| Bacterial species | Strain collection | MAF (%) | Variant GWAS Effect size (odds ratio) | Burden GWAS |
|-------------------|-------------------|---------|-------------------------------------|-------------|
|                   |                   |         | Small (1.5) Moderate (5) Large (10) Very large (100) | Small (1.5) Moderate (5) Large (10) Very large (100) |
| E. faecium        | Species-wide (n = 1432) | 1       | - - - - | - - - - |
|                   |                   | 2.5     | - - - - | - - - - |
|                   |                   | 5       | - - - - | - - - - |
|                   |                   | 10      | - - 1200 500 400 | - - 900 700 400 |
|                   |                   | 25      | - - 1200 500 400 | - - 900 700 400 |
|                   | Single-clade (n = 1531) | 2.5     | - - - - | - - - - |
|                   |                   | 5       | - - - - | - - 1300 900 |
|                   |                   | 10      | - - 1200 800 500 | - - 1100 700 400 |
|                   |                   | 25      | - - 1100 700 400 | - - 600 300 200 |
| K. pneumoniae     | Species-wide (n = 2628) | 1       | - - - - | - - - - |
|                   |                   | 2.5     | - - - - | - - 2000 1300 1000 |
|                   |                   | 5       | - - 2000 1200 800 | - - 1000 700 500 |
|                   |                   | 10      | - - 800 600 500 | - - 700 400 300 |
|                   |                   | 25      | - - 300 200 100 | - - 400 200 200 |
|                   | Single-clade (n = 1193) | 2.5     | - - - - | - - - - |
|                   |                   | 5       | - - - - | - - 1100 800 |
|                   |                   | 10      | - - - - | - - - - |
|                   |                   | 25      | - - 900 600 300 | - - 700 400 300 |
| M. tuberculosis   | Species-wide (n = 2655) | 1       | - - - - | - - - - |
|                   |                   | 2.5     | - - - - | - - 2000 1400 1000 |
|                   |                   | 5       | - - - - | - - 1400 1000 700 |
|                   |                   | 10      | - - - - | - - 1500 1200 600 |
|                   |                   | 25      | - - 1300 800 500 | - - 900 500 200 |
|                   | Single-clade (n = 1139) | 0-1     | - - - - | - - - - |
|                   |                   | 2.5     | - - - - | - - - - |
|                   |                   | 5       | - - - - | - - 800 600 |
|                   |                   | 10      | - - 900 600 500 | - - 900 500 300 |
|                   |                   | 25      | NA 400 200 100 | - - 600 300 200 |

MAF minor allele frequency, NA no variants available with that MAF, - non-detectable with 80% power.

Results of running GWAS power calculations applying the phenotype simulation approach (binary phenotype, full heritability assumed). This table shows the minimum sample sizes required to detect acquired variants (i.e., mutations in the bacterial chromosome) of different effect sizes (in odds ratio units) and MAF using a variant or burden test GWAS with 80% power, in both species-wide and single-clade populations. Supplementary Figs. 2 and 3 show the PowerBacGWAS plots from which the results in this table were extracted from MAF minor allele frequency, NA no variants available with that MAF, - non-detectable with 80% power.
**Discussion**

In this work, we showed how existing collections of bacterial genomes can be harnessed to conduct power calculations for bacterial GWAS. Investigators can apply our approach as part of their study design to determine how many strains they would need to sequence and/or phenotype to successfully identify statistically significant associations. Power calculations can also be applied post hoc, to report on the limit of detection in terms of the lowest MAF and effect sizes detectable by GWAS in the bacterial population of study. Either way, conducting power calculations will require making a set of assumptions as to the type of causal genotypes (i.e. caused by the acquisition of genes or mutations), their MAF, effect sizes and heritability.

We implemented two approaches to perform power calculations, here labelled as sub-sampling and phenotype simulation approaches. The former requires a known genotype-phenotype relationship in the population of study. We chose antibiotic susceptibility phenotypes, as determined by in vitro susceptibility testing, as they were readily available for the strain collections we used; and because the genetic basis of AMR phenotypes is generally well understood. The advantage of using AMR genes is that

---

**Fig. 3 Effect of degree of homoplasy on the power to detect SNPs obtained using the phenotype-simulation approach.** These plots show the sample sizes required to detect causal SNPs of different effect sizes (in odds ratio units, showed as different colours) and degrees of homoplasy (number of independent acquisitions, shown as different point shapes) when simulating binary phenotypes (full heritability assumed). The power calculation results presented here are those for SNPs of 10% MAF, in both species-wide (panels a, c, e) and single-clade populations (panels b, d, f), see Supplementary Table 4 for SNPs of different MAF. The power in Fig. 3e, i.e. for SNPs with 50–100 homoplasy steps in *M. tuberculosis* population, are particularly noisy due to the low number of SNPs in this population arising 50–100 times in the phylogeny (only 9 variants), which makes power estimates of such a small sample to fluctuate.

*M. tuberculosis*, lower sample sizes were required in the single-clade population compared to the species-wide, to detect SNPs of the same MAF, effect size and degree of homoplasy (Supplementary Table 4). In *K. pneumoniae*, we observed the opposite, higher sample sizes were required in the single-clade population. In *E. faecium*, similar sample sizes were needed in both populations to detect highly homoplastic SNPs (acquired 10–50 and 50–100 times) but higher in the single-clade population to detect low-homoplastic SNPs (acquired 1–5 and 5–10 times).
they are common and have high effect sizes; thus, the original population can be sub-sampled and AMR phenotypes modified to achieve the desired reduction in MAF and effect sizes. The limitations are that AMR phenotypes may not always be available or balanced in the population of study. This analysis is also constrained by the underlying genetic architecture, and the maximum MAF and effect size of causal genotypes. To overcome these limitations, we implemented the phenotype simulation approach which allowed us to test the effect of a wider range of parameters (i.e. effect size and heritability) by simulating phenotypes from existing genetic variants of different MAF and homoplasy.

Although it was expected that higher values of these variables (i.e. MAF, effect sizes, heritability and degree of homoplasy) would lead to an increase in power, we were able to determine the exact sample sizes for different combination of parameters and in different populations. Sample sizes required to detect causal acquired genes in a pan-genome GWAS were similar regardless of the bacterial species and population. This was not the case for the detection of causal SNPs, which depended heavily on the population. This may be due to pan-genome sizes being relatively comparable between species and populations, as well as a higher degree of genetic diversification in chromosomal genes (number of SNPs). Here we show that MAF, homoplasy and effect size of causal SNPs all have a measurable effect in the sample sizes required to detect them. The fact that the magnitude of such effect varies by population points to population-specific factors having an influence too. Factors that may affect the performance of GWAS, and thus the estimated power, include the accuracy of phylogenetic reconstructions, which may be challenging to obtain in bacteria with high recombination rates, the degree of population stratification and patterns of linkage disequilibrium. These factors highlight the fact that the power estimated using samples from one population may not hold true for others, and support our recommendation to conduct power calculations using real genotypes for the specific bacterial population of study, which will capture real patterns of population structure and linkage disequilibrium. This should be feasible for well-studied organisms given the large and increasing availability of whole-genome sequenced strains in public repositories.

Our study has several limitations. Here we used Snippy as the bacterial SNP-calling pipeline choice, as it has been shown to minimise false positives calls. However, a limitation of Snippy is that missing SNP calls are not retained in Snippy’s output consen sus sequence, so SNP MAF were calculated without considering SNP missing calls. Still, we expect this to have little effect on power estimates, as SNPs chosen to simulate phenotypes are randomly selected multiple times, which means that the power calculated across simulations will account for the multiple and most common missing call rates present in the population. We used a single GWAS tool (PySeer) and method (linear mixed model) to conduct GWAS. Recent work has shown that the power to detect causal variants depends on the GWAS method employed. It was out of the scope of our study to benchmark and give recommendations on individual GWAS methods. Our pipeline can be easily adapted to accommodate other GWAS tools, as multiple steps in the pipeline, such as variant sampling or phenotype simulations, are independent of the GWAS method used. A requirement to run the phenotype-simulation approach is that the ancestral state of genetic variants can be reconstructed so that these can be selected based on their degree of homoplasy. This prerequisite may not be possible for bacterial populations with high recombination rates. Another limitation is that sequenced genomes from the population of interest must be already available. However, for species that are not well-studied, power calculations can be performed by simulating bacterial populations from a reference genome, as previously described.

Further work is needed to perform power calculations for complex bacterial phenotypes involving multiple loci (e.g. epistatic effects). It was out of the scope of this work to investigate and report false positives rates. False positives in bacterial GWAS may arise from a variety of reasons, including the degree of genotype missingness, sequencing batch effects, regions in the genome that are hard to genotype, or the degree of stratification and linkage disequilibrium of causal variants in the population. Future work is needed on how best identify and account for factors that give rise to false positives in bacterial GWAS.

In conclusion, power estimates will only apply to the bacterial population for which power calculations were performed from, and may not be generalisable to other populations. We thus recommend the use of existing genomes of the species and population of interest. In our approaches, only phenotypes were changed or simulated – bacterial genotypes and populations were not in any case simulated or modified. Given the inherent differences among bacterial populations, we believe our approach will yield realistic estimates of the sample sizes required to conduct successful GWAS.

Methods
Choice of bacterial populations. Three bacterial species were chosen to represent a gram-negative organism (E. faecium) and a species of limited genetic diversity (M. tuberculosis), respectively. For each species, a population representative of the species-wide strain diversity was obtained from available collections of whole-genome sequenced strains. A subset of this species-wide population with lower strain diversity, made up of samples from a single clade, was additionally selected (single-clade population).

For E. faecium, we used a strain collection isolated from a variety of sources in the UK of 1432 isolate genomes from livestock and meat (n = 256), wastewater treatment plants (n = 383), bloodstream infections (n = 782) and 11 NCTC strains. The E. faecium single-clade population consisted of 761 clade A1 isolates drawn from a haematology study, where the original population (of 1477 isolates) was further de-duplicated to retain a single representative of clade A1 per subtype (strain type), and patient, and reduced down to 227 and 534 isolates from faecal and ward environmental sources, respectively. To increase the population of clade A1 genomes, we additionally included genomes from a UK hospital study (n = 292) and a UK nation-wide (n = 478) studies, which increased the population size to 1531 clade A1 genomes.

The K. pneumoniae collection was assembled from seven studies and consisted of 2628 isolates. The selected publications describe nation-wide or international isolate collections and include human, animal and environmental samples from Africa, Asia, the Caribbean and Europe including their antimicrobial susceptibility phenotypes. We did not include collections from a single local source, for example a single hospital, to reduce the possibility of including closely related isolates with low genetic diversity originating from a local outbreak. The K. pneumoniae single-clade population consisted of 239 CC258 isolates from this collection, plus 396 and 558 CC258 isolates from an extra two studies.

M. tuberculosis, we chose a collection of clinical isolates (n = 2655) generated as part of a global drug resistance project and representing the four main human-infecting M. tuberculosis complex (MTBC) lineages (lineages 1 to 4). The M. tuberculosis single-clade population consisted of 1139 isolates belonging to the most common sub-lineage (sub-lineage 4.3) in this global collection.

Genome analysis pipelines. Raw sequencing data was analyzed with the goal of obtaining three standard files: a multi-sample VCF, a pan-genome table and a phylogenetic tree. For K. pneumoniae genomes, Kleborate was used to determine the species of all isolates, of which those with a weak species match or a match to any species other than K. pneumoniae were excluded. Genomes with >1000 contigs were also excluded. For M. tuberculosis and E. faecium, genomes, the quality control filters applied to discard bad quality genomes are described in the original publications.

For all collections, draft assemblies were generated using an automated de novo assembly pipeline based on Velvet and annotated using Prokka. Pan-genomes were computed using Panaroo v1.2.3 with strict stringency mode. Reads were mapped to the reference genome of each bacterial organism using Snippy v4.6.0. The reference genome for each species was specifically, the K. pneumoniae HS11286 (NC_016845.1), E. faecium Aus0004 strain (CP003351), and M. tuberculosis H37Rv (GenBank accession NC_000962.3) reference genomes were chosen. Snippy was used as it is recommended as a general purpose bacterial SNP-calling pipeline and has been shown to minimise false positives. Whole-genome alignments were created by keeping a version of the reference genome with only substitution variants (i.e. SNPs but not indels) instantiated (i.e. Snippy’s consensus.sbv output file). Single-nucleotide polymorphisms (SNPs) were extracted from whole-genome alignments using snp-sites v2.5.1 and saved as a multi-sample VCF files (the one used for power
The use of PastML and PLINK tools in the pipeline, VCF and Roary-delimited binary matrix with the presence and absence of each gene in each sample. MAF and effect size of causal variants are calculated. Second, and for each parameter combination as specified in the parameters file. Finally, prepare_gwas_runs_subsampling.py outputs a bash script with GWAS runs (as many as sub-samples) and a CSV file with all parameter combinations used. Preyser v1.3.55 was used to run the GWAS using the linear mixed model (LMM) to account for population structures. The LMM is calculated from the phylogenetic tree using PySeer’s script phylogeny_distance.py and thus is kept for all GWAS analyses (SNP, burden testing and pan-genome GWAS) applied to the same sample. Finally, the script process_gwas_runs.py is used to extract the LMM adjusted p-values of causal variants from Preyser output files; and the R script plot_gwas_runs_subsampling.R to plot the results.

Implementation of PowerBacGWAS pipeline: phenotype simulation approach.

We implemented a second approach to conduct power calculations for when a genotype-phenotype relationship is not known in the population, for both binary and quantitative phenotypes. In brief, this approach consists in sampling existing genes from the pan-genome, variants from a VCF file or mutated regions (i.e. for burden testing) meeting a predefined MAF and degree of homoplasy, and then simulate phenotypes from these variants with a pre-defined effect size and sample size. The wrapper scripts prepare_gwas_runs.py and prepare_gwas_runs_roary.py implement this approach for VCF variants and the pan-genome, respectively (Supplementary Fig. 4). In addition to the variant file (VCF or pan-genome), this script requires a table with the number of homoplasies per variant, as produced by scripts ancestral_state_reconstruction.py and ancestral_state_r-plot.py. A parameters file is also required to specify ‘causal variant sampling parameters’ (that is, range of MAF to test, level of homoplasy, number of causal variants and sampling repetitions) and ‘phenotype simulation parameters’ (range of sample sizes and effect sizes to test, and simulation repetitions, among others). The units of effect sizes are specified as odds ratios when simulating binary phenotypes or in beta units when simulating quantitative phenotypes. For a given combination of parameters, the script sample_common_variants_from_vcf.py, called within the wrapper script prepare_gwas_runs.py, reads a VCF file and randomly samples the chosen number of causal variants per sample from the indicated MAF and homoplasy level. The script outputs the list of variant IDs along with their chosen effect size in a GCTA-compliant format. The number of times this variant sampling step is repeated can be chosen in the parameters file. This was set to 10 per set of simulation parameters in the analyses presented in this manuscript. If the option of a burden test is selected, then the script outputs all variants in the regions meeting the chosen MAF (proportion of samples with any variant within a region) and homoplasy criteria (number of independent homoplasies within a region, computed by script calculate_changes_per_region.py). The script simulate_ phenotype.py using gcta.py reads the list of causal variants previously sampled, and uses the additional genetic model implemented in GCTA to simulate phenotypes. When simulating binary phenotypes with GCTA, we noted that the variable that had the biggest impact on the distribution of mutated and wildtype individuals among cases and controls, and thus association p-values, was the heritability, not so much the effect size (odds ratio) specified in the causal variants file. We thus decided not to simulate GCTA when specifying quantitative phenotypes, but only when specifying heritability values or simulating quantitative traits.

The script simulate_binary_phenotype_vcf.py (and simulate_binary_phenotype_roary.py) was written to implement a custom method to simulate binary phenotypes for a given odds ratio.

This script takes the multi-sample VCF and list of causal variants as input files; and the chosen number of cases and controls (sample size), MAF and odds ratio to be simulated as parameters. The function scipy.optimize.least_squares is used in this script to solve the following set of equations:

\[ E_1: \text{sample size} \times \text{MAF} = \text{mutated controls} + \text{mutated cases} \]

\[ E_2: \text{sample size} \times (1 - \text{MAF}) = \text{wildtype controls} + \text{wildtype cases} \]

\[ E_3: \text{cases = mutated cases + wildtype cases} \]

\[ E_4: \text{controls = mutated controls + wildtype controls} \]

\[ E_5: \text{odds ratio} = \frac{\text{(mutated cases + mutated controls)}}{\text{(wildtype cases + wildtype controls)}} \]

Where variables sample size, MAF, cases (number of cases), controls (number of controls) and odds ratio are known (i.e. specified by the user); and variables, mutated cases, wildtype cases, mutated controls and wildtype controls, defining the number of cases and controls with and without causal variants, are calculated. The script identifies which samples (i.e. isolates) in the VCF file carry the causal alleles (mutated) which ones do not (wildtype). Then, it randomly selects the number of mutated_control and mutated_cases from the pool of mutated samples and labels them as controls and cases, respectively; and selects the number of
pipeline that uses this Docker image, to automate the multiple computational software tools, modules and package dependencies of PowerBacGWAS, we built a pipeline from multiple causal variants. The pipeline is reduced to only three steps: (1) preparation of input files, (2) ancestral controls), MAF and odds ratio chosen by the user.

**Docke**r and Nextflow implementation of PowerBacGWAS. Given the multiple software tools, modules and package dependencies of PowerBacGWAS, we built a Docker image of the pipeline ([https://hub.docker.com/r/francesccoll/powerbacgwas](https://hub.docker.com/r/francesccoll/powerbacgwas)) to facilitate usage. We have additionally implemented a Nextflow pipeline that uses this Docker image, to automate the multiple computational steps and parallelise the GWAS runs. Using the Nextflow implementation, the pipeline is reduced to only three steps: (1) preparation of input files, (2) ancestral state reconstruction and (3) GWAS runs. In the latter, the user can choose the type of variant, phenotype, GWAS method and approach to power calculations. The GitHub page ([https://github.com/francesccoll/powerbacgwas](https://github.com/francesccoll/powerbacgwas)) includes instructions on how to install PowerBacGWAS via Docker and Nextflow, or locally. The Usage Wikipage ([https://github.com/francesccoll/powerbacgwas/wiki#usage]) includes sections on how to run the pipeline using the Docker/Nextflow installation ("Nextflow commands") or how to run individual scripts using the locally installation ("Individual commands"). The computational time of running PowerBacGWAS depends on the number of parameter combinations, and number of variants sampling and phenotype simulation repetitions indicated in the parameters file. All these parameters combined determine the number of individual GWAS runs. We recommend to run the Nextflow pipeline with the LSF executor, as an LSF cluster is available, for faster running times, wherein each process is submitted as a separate job. Overall, for the six bacterial datasets used in this work, PowerBacGWAS used a median of 1,670 CPU hours (interquartile range: 548 to 3542) and a median duration of 3.1 h (interquartile range: 2.7–7.6 h) when using the Nextflow LSF executor.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

The whole-genome sequences of the strain collections used in this study are available on European Nucleotide Archive (ENA) under the accessions listed in Supplementary Data 1. The whole-genome sequences of the strain collections used in this study are available on European Nucleotide Archive (ENA) under the accessions listed in Supplementary Data 1. The whole-genome sequences of the strain collections used in this study are available on European Nucleotide Archive (ENA) under the accessions listed in Supplementary Data 1. The whole-genome sequences of the strain collections used in this study are available on European Nucleotide Archive (ENA) under the accessions listed in Supplementary Data 1. The whole-genome sequences of the strain collections used in this study are available on European Nucleotide Archive (ENA) under the accessions listed in Supplementary Data 1.

**Code availability**

All scripts necessary to run the power calculations pipeline are available on Github ([https://github.com/francesccoll/powerbacgwas](https://github.com/francesccoll/powerbacgwas)). Docker images are available on [https://hub.docker.com/r/francesccoll/powerbacgwas](https://hub.docker.com/r/francesccoll/powerbacgwas). The source data of Figs. 2 and 3 can be found in Supplementary Data 2 and 3, respectively.

Received: 22 December 2020; Accepted: 25 February 2022; Published online: 25 March 2022

**References**

1. Earle, S. G. et al. Identifying lineage effects when controlling for population structure improves power in bacterial association studies. Nat. Microbiol. 1, 16041 (2016).
2. Coll, F. et al. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat. Genet. 50, 307–316 (2018).
3. Chewopreecha, C. et al. Comprehensive identification of single nucleotide polymorphisms associated with beta-lactam resistance within pneumococcal mosaic genes. PLoS Genet. 10, e1004547 (2014).
4. Salipante, S. J. et al. Large-scale genomic sequencing of extraintestinal pathogenic Escherichia coli strains. Genome Res. 25, 119–128 (2015).
5. Pidto, S. J. et al. Increasing tolerance of hospital Enterococcus faecium to handwash alcohols. Sci. Transl. Med. 10, eaar1115 (2018).
6. Shepard, S. & Didelot, X. Genome-wide association study identifies vitamin B5 biosynthesis as a host specificity factor in Campylobacter. Proceedings ... 110, 1192–1197 (2013).
7. Richardson, E. J. et al. Gene exchange drives the ecological success of a multi-host bacterial pathogen. Nat. Ecol. Evol. https://doi.org/10.1038/s41559-018-0611 (2018).
8. Nebenzahl-Guimaraes, H. et al. Transmissible mycobacterium tuberculosis strains share genetic markers and immune phenotypes. Am. J. Respir. Crit. Care Med. 195, 1519–1527 (2017).
9. Lees, J. A. et al. Genome-wide identification of lineage and locus specific variation associated with pneumococcal carriage duration. eLife 6, 1–25 (2017).
10. Chewopreecha, C. et al. Genetic variation associated with infection and the environment in the accidental pathogen Burkholderia pseudomallei. Commun. Biol. 2, 428 (2019).
11. Young, B. C. et al. Panton–Valentine leucocidin is the key determinant of Staphylococcus aureus pyomyositis in a bacterial GWAS. eLife 8, 1–15 (2019).
12. Murray, M. M. et al. Uncoupling Listeria monocytogenes hypervirulence by harnessing its biodiversity. Nat. Genet. 48, 308–313 (2016).
13. Lilje, B. et al. Whole-genome sequencing of bloodstream Staphylococcus aureus isolates does not distinguish bacteriae from endocarditis. Microb. Genomics 3, 1–11 (2017).
14. Young, B. C. et al. Severe infections emerge from commensal bacteria by adaptive evolution. eLife 6, 1–25 (2017).
15. Lees, J. A. et al. Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis. Nat. Commun. 10, 1–14 (2019).
16. Cremers, A. H. J. et al. The contribution of genetic variation of streptococcus pneumoniae to the clinical manifestation of invasive pneumococcal disease. eLife 8, 1–15 (2019).
17. Lees, J. A. et al. Large scale genomic analysis shows no evidence for pathogen adaptation between the blood and cerebrospinal fluid niches during bacterial meningitis. Microb. Genomics 3, 1–12 (2017).
18. Earle, S. G. et al. Genome-wide association studies reveal the role of polymorphisms affecting factor H binding protein expression in host invasion of Neisseria meningitidis. PLoS Pathog. 17, e1009992 (2021).
19. Young, B. C. et al. Antimicrobial resistance determinants are associated with Staphylococcus aureus bacteremia and adaptation to the healthcare environment: a bacterial genome-wide association study. Microb. Genom. 7, 700 (2021).
20. Tunjungputri, R. N. et al. Phage-derived protein induces increased platelet activation and is associated with mortality in patients with invasive pneumococcal disease. mBio. 8, 1–10 (2017).
21. Power, R. A., Parkhill, J. & de Oliveira, T. Microbial genome-wide association studies: lessons from human GWAS. Nat. Rev. Genet. https://doi.org/10.1038/nrg.2016.132 (2016).
22. San, J. E. et al. Current affairs of microbial genome-wide association studies: approaches, bottlenecks and analytical pitfalls. Front. Microbiol. 10, 3119 (2020).
23. Chen, P. E. & Shapiro, B. J. The advent of genome-wide association studies for bacteria. Curr. Opin. Microbiol. 25, 17–24 (2015).
24. Lees, J. A., Galardini, M., Bentley, S. D., Weiser, J. N. & Corander, J. pyseer: a comprehensive tool for microbial genome-wide association studies. Bioinformatics 34, 4310–4312 (2018).
25. Brynildsrud, O., Bohlin, J., Scheffer, L. & Eldholm, V. Rapid scoring of genes in microbial pan-genome-wide association studies with Scoary. Genome Biol. 17, 238 (2016).
26. Lees, J. A. et al. Sequence element enrichment analysis to determine the genetic basis of bacterial phenotypes. Nat. Commun. 7, 12797 (2016).
27. Jallard, M. et al. A fast and agnostic method for bacterial genome-wide association studies: Bridging the gap between k-mers and genetic events. PLoS Genet. 14, 1–28 (2018).
28. Farhat, M. R. et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat. Genet. 45, 1183–1189 (2013).
29. Collins, C. & Didelot, X. A phylogenetic method to perform genome-wide association studies in microbes that accounts for population structure and recombination. *PLoS Comput. Biol.*, 14, 1–21 (2018).

30. Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 19, 149–150 (2003).

31. Chow, J. W. Aminoglycoside resistance in enterococci. *Clin. Infect. Dis.*, 31, 586–589 (2000).

32. Phelan, J. E. et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. *Genome Med.*, 11, 41 (2019).

33. Coll, F. et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genre Med.*, 7, 51 (2015).

34. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.*, 81, 559–575 (2007).

35. Alcock, B. P. et al. CARD 2020: antibiotic resistance surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res.*, 48, 517–525 (2019).

36. Ishikawa, S. A., Zhukova, A., Iwasaki, W. & Gascuel, O. A fast likelihood method to reconstruct and visualize ancestral scenarios. *Mol. Biol. Evol.*, 36, 2069–2085 (2019).

37. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.*, 88, 76–82 (2011).

38. Coll, F. PowerBacGWAS v1.0.0. *Zenodo* https://doi.org/10.5281/zenodo.5950335 (2022).

Acknowledgements

This project was funded by Wellcome Trust grant (201344/Z/16/Z) awarded to Francesc Coll. This publication was supported by the Health Innovation Challenge Fund (WT09860, HICF-T5-342), a parallel funding partnership between the Department of Health and Wellcome Trust. T.G.C. is funded by the Medical Research Council UK (Grant no. MR/M01360X/1, MR/N010469/1, MR/R025576/1 and MR/R020973/1) and BBSRC UK (Grant no. BB/R01363/1). The views expressed in this publication are those of the author(s) and not necessarily those of the funders.

Author contributions

F.C. designed the study with input from J.Pa.; F.C undertook the bioinformatic analyses with contributions from T.G., S.B. and J.Pa.; T.G. and K.R. curated, analyzed and provided the *E. faecium* collections used in this study whereas S.B. did so for the *K. pneumoniae* collections. J.Pa. and T.G.C. generated, analyzed and provided the *M. tuberculosis* collections. F.C. and J.Pa. wrote the first draft of the manuscript. S.J.P. and J.Pa. supervised the study. All authors had access to the data and read, contributed and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-022-03194-2.

Correspondence and requests for materials should be addressed to Francesc Coll.

Peer review information *Communications Biology* thanks Koji Yahara and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: George Inglis. Peer reviewer reports are available.

Reprints and permission information are available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022